Despite therapeutic advances, relapsed/refractory CLL, particularly after fludarabine-based regimens, remains a major challenge for which optimal therapy is undefined. No randomized comparative data exist to suggest the superiority of reduced-toxicity allogeneic hematopoietic cell transplantation (RT-allo-HCT) over conventional chemo-(immuno) therapy (CCIT). By using estimates from a systematic review and by meta-analysis of available published evidence, we constructed a Markov decision model to examine these competing modalities. Cohort analysis demonstrated superior outcome for RT-allo-HCT, with a 10-month overall life expectancy (and 6-month quality-adjusted life expectancy (QALE)) advantage over CCIT. Although the model was sensitive to changes in base-case assumptions and transition probabilities, RT-allo-HCT provided superior overall life expectancy through a range of values supported by the meta-analysis. QALE was superior for RT-allo-HCT compared with CCIT. This conclusion was sensitive to change in the anticipated state utility associated with the post-allogeneic HCT state; however, RT-allo-HCT remained the optimal strategy for values supported by existing literature. This analysis provides a quantitative comparison of outcomes between RT-allo-HCT and CCIT for relapsed/refractory CLL in the absence of randomized comparative trials. Confirmation of these findings requires a prospective randomized trial, which compares the most effective RT-allo-HCT and CCIT regimens for relapsed/refractory CLL.
INTRODUCTION
CLL represents the most common leukemia in the western hemisphere, with 14 990 new cases in the USA in 2010. 1 New chemotherapeutic agents, immunotherapy or combinations of chemotherapy plus immunotherapy have improved outcomes, by inducing higher frequency and better quality of responses, but have not yet translated into cure of CLL. Accordingly, consideration of optimal therapy for relapsed/refractory CLL is of vital importance. Allogeneic hematopoietic cell transplantation (allo-HCT) is the only known treatment option that offers the possibility of cure for relapsed/refractory CLL at this time. 2, 3 Traditionally, administration of allo-HCT has been limited to younger patients without significant comorbidities, owing to the risk of transplant-related morbidity and mortality resulting from toxicity of myeloablative regimens. [4] [5] [6] [7] Better understanding of the importance of adoptive immunotherapy mediated by donor immune effector cells resulted in the development of less ablative preparative regimens. 8, 9 These regimens, categorized as reduced-toxicity regimens, 10 are associated with less non-relapse mortality (NRM). Accordingly, they have expanded the applicability of allo-HCT to older patients with comorbidities, who would not have been candidates for myeloablative allo-HCT earlier.
There are no prospective randomized studies that compare the efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation (RT-allo-HCT) with CCIT in relapsed/refractory CLL. Consequently, the decision to offer (or not) a RT-allo-HCT is based on uncontrolled, observational studies and empiricism. A decision analysis represents a statistical method that aids in decision making when uncertainty is present or when the superior treatment is unknown. 11 In the absence of randomized trial-based evidence on the comparative efficacy of RT-allo-HCT and CCIT for relapsed/refractory CLL, we examined these competing treatment options in a Markov decision model informed by systematic review (SR) and metaanalysis of available evidence.
MATERIALS AND METHODS
We developed a Markov decision model using the TreeAge Pro 2009 software to represent the decision of RT-allo-HCT versus CCIT for relapsed/ refractory CLL. Following a decision node of RT-allo-HCT versus CCIT, cloned Markov trees followed, which consisted of distinct health states including treatment, responsive disease post therapy (including CR and PR), progressive disease and death ( Figure 1) . We did not model a distinct GVHD state following reduced-toxicity transplantation, as the mortality threat from this complication is included in the NRM reported in the utilized literature.
Transition probabilities that define the probability of transition from one health state to another in the model were based on the SR of the literature, which was conducted to acquire available literature separately for RT-allo-HCT and CCIT for relapsed/refractory CLL. In each case, we utilized broad search terms to ensure that we captured all relevant studies. Selection of studies included prospective trials (phase III, phase II or selective phase I/II where response rates, and/or survival, and/or relapse were an intended end point and such data were extractable) and retrospective studies, or case series, that included X12 patients. For studies evaluating the role of chemotherapy, immunotherapy (limited to therapeutic monoclonal antibodies) or chemo-immunotherapy combinations, a systematic and comprehensive literature search was performed using MEDLINE databases from 1966 to 31 December 2010 and supplemented by a hand search of references. The following search strategy was used to identify potential studies: ( ). Studies not specifically intended for CLL were excluded. Data reported solely in meeting abstracts were excluded. Data were extracted on the following primary outcomes: treatment-related mortality, overall response rate (ORR) (CR and PR response), stable disease or progressive disease , progression from responsive disease, and survival. Our search identified 83 publications, of which 34 met the inclusion criteria ( Figure 2a ). In two cases [refs 31, 32 ], data represented a follow-up study and were complementary. Thus, the final number of studies evaluated was 33 (see Supplementary Table 1) . Similarly, for studies evaluating the role of RT-allo-HCT, a systematic and comprehensive literature search was performed using MEDLINE databases from 1966 to 31 December 2010 and supplemented by a hand search of references. The following search strategy was used to identify potential studies: ((((('Leukemia, Lymphocytic Table 2) . 18, [46] [47] [48] [49] [50] [51] [52] [53] [54] From the primary articles identified, the probabilities of each outcome of interest were abstracted and summarized as a pooled estimate using random-effects meta-analysis. The resultant pooled estimate was used to define transition probabilities in the model. The probability of each outcome was converted to a rate, adjusted to adhere to a month-cycle length, and then converted back to the final probability utilized in the decision model. Health-state utilities were estimated from available literature for calculation of quality-adjusted life expectancy (QALE) in a quality-adjusted model. Analyses were performed using cohort analysis. Future discounting was not included. Assumptions were extensively tested, and the model was externally validated by comparison of survival outcomes generated by the model with those reported in the relevant primary literature. In addition, sensitivity analyses were performed to challenge the transition probability estimates and health state utilities.
Base case assumption A base-case age of 50 was assumed in this analysis, which was in keeping with the age distribution included in the relevant trials of RT-allo-HCT or non-HCT therapies for relapsed/refractory CLL. A range of potential ages (30-70 years) was examined in sensitivity analysis.
State transition probabilities
For each of the model transition probabilities, estimates were produced separately from relevant literature for RT-allo-HCT and CCIT. The probability of NRM (pDieNRM) was defined by death without CLL relapse after therapy, as defined in the primary literature. This probability was limited to 3 months in the CCIT arm to model an anticipated period of risk for toxicity. Conversely, NRM was operational in the RT-allo-HCT arm for 3 years to Efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation MA Kharfan-Dabaja et al model both early transplant death and late NRM from chronic GVHD and infectious complications; in sensitivity analysis, we explored the impact of prolonged duration of post-HCT NRM, specifically for 3, 5, 7 and 10 years post HCT. A variable (TRM_ force) was created to estimate NRM in the HCT arm as a multiple of the estimated NRM in the CCIT arm for the purpose of sensitivity analysis as well. The probability of dying from relapse (pDieREL) was defined by death following CLL relapse after therapy, as per the primary literature definition. The probability of response (pResponse) was defined as the ORR, including the sum of CR and PR following therapy. The probability of progression (pProgress) was defined as progression from the responsive state (CR þ PR) to more advanced disease.
Health-state utilities
Health-state utilities represent the quality of life (QOL) associated with each state, allowing the estimation of QALE. No data evaluating QOL in CLL were identified; hence, meta-analysis from primary literature was not possible. Representative values were used from other relevant literature as follows: QOL values range from 0 to 1, with 0 representing death and 1 representing optimal health. We assumed that the starting state of treatment was assigned a utility of 1.0, which represents the starting state of optimal health. The health state responsive disease was defined separately for the RT-allo-HCT and CCIT arms of the model: the health state responsive disease was assigned a utility of 0.9 for the RT-allo-HCT arm, modeled after 'mean utility for life with chronic GVHD after transplantation' by Lee et al. 55 We assigned a utility of 0.979 for the responsive disease state in the CCIT arm, modeled after 'mean utility for life without chronic GVHD after transplantation' by Lee et al. 55 This was chosen based on a lack of specific data to guide assignment of state utility to patients post chemotherapy for CLL, and an assumption that this utility would be superior to that of patients post HCT, who may be affected with transplant complications including chronic GVHD. The state stable/progression was assigned a utility of 0.57 in the reduced-toxicity allo-HCT arm after 'survivors who developed recurrent disease after BMT' and 0.79 for the CCIT arm after 'survivors who developed recurrent disease after chemotherapy', derived by standard gamble methods and reported by Sung et al. 56, 57 State utility of the dead state was 0. These assumptions were tested in sensitivity analyses across a range of plausible values.
Model validation
The model structure, definitions and assumptions were tested, and we also externally validated the projected survival outcomes from the model cohort analysis against the primary literature for both RT-allo-HCT and CCIT for relapsed/refractory CLL.
RESULTS
Data were meta-analyzed under a random-effects model for the purpose of obtaining a pooled proportion for each variable represented in the model (Table 1) . By using the methods described above, an unadjusted Markov model was constructed and populated with state transition probabilities from the above pooled estimates. Probabilities were adjusted to adhere to a month-cycle length in the model. A separate quality-adjusted model incorporated the relevant health-state utilities for calculation of QALE. In the unadjusted model, overall life expectancy was superior in the RT-allo-HCT arm, with a 10-month survival advantage (Table 2) .
In sensitivity analyses, we challenged the base-case assumptions and transition probabilities in the unadjusted model. The purpose of these analyses is to examine how the outcome (that is, best therapeutic strategy) changes when key variables are modified. These demonstrated intuitive relationships, whereby increasing probability of adverse variables (NRM, progression from CR/PR state, death from relapse) resulted in decreased overall life expectancy and increasing probability of beneficial variables (response to therapy) resulted in increased overall life expectancy. Advancing age resulted in lower overall life expectancy, but RT-allo-HCT remained superior to non-HCT therapy throughout this range. Similarly, we examined the impact of a range of plausible values for each state transition probability in the model through sensitivity analyses; this range was defined by the upper and lower limits of the 95% confidence interval from the pooled estimate in the random-effects meta-analysis. The model was sensitive to variation in these transition probabilities, but RT-allo-HCT remained superior to CCIT across the range of potential values supported by the meta-analysis. Given the heterogeneity in therapeutic regimens utilized in the included RT-allo-HCT and CCIT, the impact of variation in pResponse for both modalities was of particular interest. However, although the model was sensitive to changes in pReponse for both, no transition point (that is, change in best therapeutic strategy) was observed in the optimal strategy. As treatment mortality is a particular concern following allo-HCT, we studied the impact of post-HCT TRM extensively. Interestingly, when the variable 'TRM force' was increased beyond a threshold value of 4.3 (which would B34.4% NRM following HCT), the optimal strategy changed such that allo-HCT was then inferior to CCIT (Figure 3 ). Although this magnitude of NRM lies outside of the 95% confidence interval for NRM following RT-allo-HCT by our meta-analysis, this extent of NRM has been previously observed following myeloablative allo-HCT for older adults with relapsed/refractory CLL. This has important implications for the utility of myeloablative allo-HCT for relapsed/refractory CLL. In addition, we examined the impact of TRM force and pResponse in the RT-allo-HCT arm of the model with two-way sensitivity analysis (Figure 4) . A two-way sensitivity analysis determines how the best therapeutic strategy changes in the context of simultaneously varying two variables (that is, TRM and response) of interest. This analysis demonstrates the impact of TRM and suggests that RT-allo-HCT remains superior to CCIT through a broad range of overall response when HCT-related NRM is maintained below B3-5 times that observed after CCIT. Finally, we considered prolonged duration of risk for NRM after RT-allo-HCT beyond the base assumption of 3 years. The overall life expectancy following RT-allo-HCT in the model declined from 35 months to 31, 30 and 30 months, respectively, for the 5-, 7-and 10-year duration of risk for NRM following HCT. Importantly, this analysis assumed constant probability of NRM over these prolonged time frames, and does not specifically model differential risk for NRM according to the presence and severity of chronic GVHD. Acknowledging these considerations, this sensitivity analysis supports the superiority of RT-allo-HCT.
Excluded studies
The quality-adjusted model also supported the superiority of RT-allo-HCT over CCIT, with a 6-month advantage in QALE (Table 2) . Sensitivity analyses were again performed for base-case age and all transition probabilities. The range examined in each mirrored the 95% confidence interval of the pooled estimate in the random-effects meta-analysis. These analyses demonstrated a consistent superiority for RT-allo-HCT over CCIT for each across the range of values supported by the meta-analysis. We next examined a broad range of potential values (0.01-0.9) for the health-state utility associated with each of the model health states ( Figure 5 ). Declining state utility for the 'initial QOL' associated with the starting treatment state led to worsened QALE but did not alter the above conclusions. Declining state utility for progressive disease in the CCIT arm led to worsened QALE, and therefore RT-allo-HCT remained superior throughout. Declining state utility assigned to progressive disease in the HCT arm led to worsened QALE; below a utility of 0.047, there was a transition whereby CCIT became the optimal strategy. In the analysis of state utility for responsive disease after CCIT, declining state utility led to worse outcomes for non-HCT therapy, and therefore continued superiority for RT-allo-HCT. Interestingly, in the sensitivity analysis for responsive disease following RT-allo-HCT, there was a transition point such that non-HCT therapy offered superior QALE below a value of 0.603. This relationship is of particular relevance, as QOL is threatened by GVHD and other complications following RT-allo-HCT. However, this degree of impairment is lower than the published value (state utility of 0.9) for those affected by chronic GVHD following allo-HCT, 55 again consistent with the superiority of RT-allo-HCT over CCIT.
DISCUSSION
Despite advances in treatment of CLL, refractoriness to fludarabine-based therapy or relapse after initial response, particularly within 12-24 months, remains a major clinical challenge. Available therapeutic options for relapsed/refractory CLL include CCIT, and also allo-HCT. Given the excessive mortality associated with myeloablative conditioning, RT-allo-HCT has been studied, with evidence supporting its curative potential in relapsed/refractory CLL. These competing therapeutic options carry differential risk for toxicity and potential benefits. However, no high-quality prospective comparative data exist, to date, to support the superiority of CCIT over RT-allo-HCT in this setting. Accordingly, we constructed a decision model examining these therapeutic options, as this analytic approach provides a systematic integration of these competing risks and benefits, and substantiates an optimal approach to maximize OS and QALE in relapsed/refractory CLL.
The model consistently demonstrates superiority of RT-allo-HCT over non-transplantation therapies for relapsed/refractory CLL. As the probability estimates utilized in the model result from the SR and meta-analysis of available literature for these competing therapeutic strategies, the conclusions are informative. The major strength in this approach is that the rigorous inclusion criteria, methodical literature searching and integrative synthesis of these data provide comprehensive and unbiased assessment of the available literature. Our findings show that offering a RT-allo-HCT in relapsed/refractory CLL results in improved life expectancy and QALE compared with CCIT. Superiority of RT-allo-HCT persisted in sensitivity analyses, which examined a range of values for each model transition probability supported by our meta-analysis. These analyses challenge the uncertainty in these estimates, and thereby further strengthen this conclusion. We recognize potential bias in data utilized for this analysis, as included studies are not randomized clinical trials. Although we challenged uncertainty in the included model variables through sensitivity analysis, these analyses are not based on probabilistic estimates of all possible variables, and hence we cannot likely identify the extent of bias. However, in the absence of randomized, prospective comparative data examining RT-allo-HCT and non-transplantation therapies, this analysis provides evidence to guide management of relapsed/ refractory CLL.
We acknowledge the potential limitations to this analysis. First, data for CCIT were obtained in some cases from studies published before the year 2000 or included agents not considered common practice nowadays; 23, 33, 36, 39 conversely, all analyzed studies evaluating RT-allo-HCT were published between 2003 and 2010. Although this raises potential concern for underestimation of the beneficial effect of non-transplant therapy, the probability estimates utilized in the model result from a SR and metaanalysis of available literature, thus providing a range of possible values based on totality of evidence, rather than selection of individual references in an unstructured and biased manner. In addition, there is insufficient evidence available to demonstrate the superiority of a particular CCIT program in the relapsed/ refractory setting, thus supporting no single standard best approach.
Second, there is a wide range of reported TRM among various CCIT published trials analyzed herein, resulting from inherent differences in toxicity of individual therapies, as well as heterogeneity in patient-, disease-and comorbidity-based risks among studies. NRM reported after chemotherapy and RT-allo-HCT, particularly that those patients selected for allo-HCT over chemotherapy may have had more favorable disease-risk features (e.g. disease, comorbidities, performance status) compared to those selected for chemotherapy trials despite the perception that older and more infirm patients can tolerate RT-allo-HCT. As the true NRM may be greater for RT-allo-HCT than what has been reported in the literature, we examined a range of potential values for NRM through a variable 'TRM force' (defined as a multiple of the NRM in the chemotherapy arm). Our baseline assumption was a 'TRM force' of 2, meaning that we assumed this risk was twice that of non-transplant therapies. In sensitivity analysis for this variable, the model was sensitive to increasing TRM, but the optimal strategy remained RT-allo-HCT for the range of values supported by the meta-analysis. Interestingly, increasing the TRM following HCT to levels that approximate that previously realized with myeloablative conditioning and allo-HCT undermined the superiority of HCT. This finding demonstrates the importance of treatment toxicity as an important determinant of outcome, and supports the overall consensus opinion that a myeloablative conditioning with allo-HCT is not the preferred option in relapsed/ refractory CLL. Third, meta-analyzed data from various studies, evaluating CCIT or RT-allo-HCT studies, used to populate this Markov decision model may have not necessarily involved subjects with similar patient and disease characteristics among the treatment arms. As data source represents aggregate data, rather than individual subject data, it is not possible to assert that patients are indeed comparable among different treatment groups. For example, patients in either group are not receiving therapy at a specific stage of their disease (that is, second-line vs third-line and so on), but rather evaluated within the broader context of 'relapsed/ refractory' disease. The heterogeneity in the burden of prior therapies received may certainly influence the outcome of the studied regimen across individual trials. Specifically, those with progression despite greater number of prior therapies may have inferior response to the studied therapy and greater risk for cumulative treatment-related toxicity. Conversely, as chemosensitivity is a known favorable prognostic factor in patients undergoing allo-HCT for CLL, this introduces added bias.
In addition, there is heterogeneity in representation of prognostically relevant molecular markers. Some studies were published before identification, and incorporation into clinical practice, of prognostic markers such as adverse chromosomal aberrations, unmutated IgVH, or ZAP-70, among others. [58] [59] [60] Few studies have targeted specific subgroups of CLL (such as ZAP-70 positivity or poor-risk mutations such as 17p-and 11q-), whereas others have not. Again, the aggregate nature, and in some cases the unavailability, of such data did not permit to take into account these prognostic factors when conducting this analysis, hence representing a potential flaw in this type of analysis. However, more restrictive inclusion criteria realistically would limit the ability to conduct therapeutic trials in this condition.
This decision analysis has been informed by rigorous SR and meta-analysis of the available literature; nevertheless, the observational nature of the studies analyzed and included herein remains a major limitation. The ideal approach to confirm these findings would include the conduct of a prospective randomized trial comparing the most effective CCIT regimen against the most effective RT-allo-HCT regimen. Until such evidence becomes available, these patients ought to be offered an opportunity to consider a RT-allo-HCT.
